search
Back to results

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form (SEIPA-FPIES)

Primary Purpose

Food Protein Induced Enterocolitis Syndrome (FPIES)

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
allergy test
Sponsored by
Fondation Lenval
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Food Protein Induced Enterocolitis Syndrome (FPIES) focused on measuring Non IgE mediated food allergy, FPIES,, children

Eligibility Criteria

undefined - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age from 0 to 17 years old,
  • seen in allergologist visit for acute FPIES, due to history of suggestive clinical symptoms, confirmed by the criteria published in 2017 in the JACI (Nowak-Wegrzyn et al, JACI 2017), or by an oral food challenge for diagnosis in the absence of the requested clinical criteria,
  • affiliated to social security (public healthcare system)
  • signed consent of one of the parents or the holder of parental authority

Exclusion Criteria:

  • Associated pathology that may contraindicate OFC at the discretion of the investigating physician. In particular justifying permanent treatment with a beta-blocker or an angiotensin-converting enzyme inhibitor.

Sites / Locations

  • Chu AngersRecruiting
  • Chi Robert BallangerRecruiting
  • Chu Clermont-FerrandRecruiting
  • Hopital Civils de ColmarRecruiting
  • Chu Grenoble
  • Ch HaguenauRecruiting
  • Chr Lille Hopital Jeanne de FlandreRecruiting
  • Hopital Saint Vincent de Paul Ghicl
  • Hopital Civil de LyonRecruiting
  • Chu MontpellierRecruiting
  • Chu NancyRecruiting
  • Cabinet Berlioz
  • Hôpitaux Pédiatriques de Nice CHU-LenvalRecruiting
  • Aphp Armand Trousseau
  • Hopital Ambroise Pare AphpRecruiting
  • Hopital Necker Enfants Malades Aphp
  • Hopital Robert Debre Aphp
  • Chu RouenRecruiting
  • Cabinet Chabbert

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

FPEIS children

Arm Description

Outcomes

Primary Outcome Measures

tolerance acquisition
The acquisition of tolerance will be defined by negative OFC or accidental intake of the food at home tolerated according to parents discussion

Secondary Outcome Measures

population description
The description of the population included will be made according to the clinical, the demographic data, the allergy tests, the history of the disease
IgE sensitization
IgE sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control) and/or the presence of specific IgE antibody on a blood sample (≥0.35 kU/L).
food sensitization
food sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control)
IgE-mediated allergy
IgE-mediated allergy is defined by the demonstration of clinical symptoms related to the presence of these specific IgEs.
IgE-dependent allergy
IgE-dependent allergy will be defined by the appearance of symptoms a few minutes to 2 hours after ingestion of the food, with skin signs (urticaria, angioedema) and/or respiratory symptoms (dyspnea, laryngospasm, cough, bronchospasm ); digestive and neurological signs being potentially common with the diagnosis of FPIES
multiple FPIES
A multiple FPIES will be defined by the presence of clinical symptoms of FPIES for at least two different foods
Atopic comorbidities
Atopic comorbidities will be defined by asthma, allergic rhinitis, atopic dermatitis, and eosinophilic esophagitis

Full Information

First Posted
July 29, 2022
Last Updated
September 28, 2023
Sponsor
Fondation Lenval
search

1. Study Identification

Unique Protocol Identification Number
NCT05528900
Brief Title
A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form
Acronym
SEIPA-FPIES
Official Title
Pathways of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form : a Multicentre Prospective Study - National FPIES Observatory
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2023 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
October 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Lenval

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Food protein induced enterocolitis syndrome (FPIES), is a non-IgE mediated food allergy (FA) which seems to expand, and occurring in infancy. This disease is usually unknown by clinicians. In 2017, an international workgroup of American Academy of Allergy, Asthma and Immunology published clinical criteria to specify the diagnosis. However, there is a lack of information in literature for describe the evolution and atypical phenotypes. In addition, no prospective French series has been published to date. The aim of the study is to collect clinical features and allergy testing of children who have acute form of FPIES at diagnosis and during evolution during three years
Detailed Description
Food protein induced enterocolitis syndrome (FPIES), is a non-IgE mediated food allergy (FA) which seems to expand, and occurring in infancy. Prevalence of FPIES is unknown. In 2011, Katz published cumulative incidence of cow 'milk FPIES of 3 per 1000 new-borns, from prospective birth cohort in Israel. The offending food depend on the country, probably in relation to eating habits. Cow's milk (CM) is most commonly incriminated and can lead to a chronic digestive disease or in its acute form with potentially life-threatening vomiting/diarrhoea/dehydration, confusing with anaphylaxis. Rice and oat in US, or fish and egg in France are the solid food most often implicated. This disease is usually unknown by clinicians. Its diagnostic is based on clinical history, and differential diagnosis elimination. In 2017, an international workgroup of American Academy of Allergy, Asthma and Immunology published clinical criteria to specify the diagnosis and management. According to this last definition (JACI 2017), patient have to meet the major criterion and at least 3 minor criteria. Major criterion is vomiting in the 1- to 4-h period after ingestion of the suspect food and absence of classic IgE-mediated allergic skin or respiratory symptoms. Minor criteria are : A second (or more) episode of repetitive vomiting after eating the same suspect food, Repetitive vomiting episode 1-4 h after eating a different food Extreme lethargy with any suspected reaction Marked pallor with any suspected reaction Need for emergency department visit with any suspected reaction Need for intravenous fluid support with any suspected reaction Diarrhea in 24 h (usually 5-10 h) Hypotension Hypothermia Skin prick test et IgE antibody are negative except atypical FPIES. Acute management begins with clinical evaluation, then administer normal saline bolus quickly. Parenteral ondansetron can be used to stop vomiting. Nutritional management implicate elimination of the offending foods. Only the oral food challenge in hospital can be done to determine resolution of FPIES after a long time of no symptom. The age of tolerance, depend of the food. The average age of acquiring tolerance for cow's milk changes in the literature, around 8-10 months in Korea, around 1 year in Israel, around 5 years in the United States. There is no data in France on the recovery age of CM-FPIES. However, there is a lack of information in literature for describe the evolution and atypical phenotypes. In addition, no prospective French series has been published to date. Our work is a national prospective study, which will collect news cases of acute FPIES diagnosis in sixteen French centres. Main objective: To determine the rate of acquisition of tolerance by food at 1 year, 2 years, 3 years post inclusion. Secondary objectives: Description of a population of children with newly diagnosed FPIES. 2. Describe the rate of patients with FPIES progressing to IgE sensitization whatever the food at 1 year, 2 years, 3 years post inclusion. 3. Determine per food the rate of FPIES patients evolving towards IgE sensitization at 1 year, 2 years, 3 years post inclusion. 4. Describe the rate of patients with FPIES progressing to clinical symptoms of IgE-mediated allergy, whatever the food, at 1 year, 2 years, 3 years post inclusion. 5. Determine, by food, the rate of FPIES evolving towards clinical symptoms of IgE-mediated allergy at 1 year, 2 years, 3 years post inclusion. 6. Describe the rate of patients with multiple FPIES at each time point of the study. 7. Describe at each time the rates of patients with personal atopic comorbidities. The inclusion period will last three years, and the follow up of each patient will last three years. Allergologist will see the patient at inclusion visit, then one time a year. If the patient does not acquire tolerance, an oral food challenge (OFC) in hospital will lead to answer. The aim of our work will help allergologist to manage FPIES children, with French specificities in offending food, and tolerance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Food Protein Induced Enterocolitis Syndrome (FPIES)
Keywords
Non IgE mediated food allergy, FPIES,, children

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
FPEIS children
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
allergy test
Intervention Description
allergy test are oral food challenge , prick test and IgE blood rate
Primary Outcome Measure Information:
Title
tolerance acquisition
Description
The acquisition of tolerance will be defined by negative OFC or accidental intake of the food at home tolerated according to parents discussion
Time Frame
through study completion, an average of 6 years
Secondary Outcome Measure Information:
Title
population description
Description
The description of the population included will be made according to the clinical, the demographic data, the allergy tests, the history of the disease
Time Frame
through study completion, an average of 6 years
Title
IgE sensitization
Description
IgE sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control) and/or the presence of specific IgE antibody on a blood sample (≥0.35 kU/L).
Time Frame
at 1 year, 2 years, 3 years post inclusion
Title
food sensitization
Description
food sensitization is defined by the positivity of an immediate-read skin test (wheal of the prick test greater than half of the positive histamine control)
Time Frame
at 1 year, 2 years, 3 years post inclusion
Title
IgE-mediated allergy
Description
IgE-mediated allergy is defined by the demonstration of clinical symptoms related to the presence of these specific IgEs.
Time Frame
at 1 year, 2 years, 3 years post inclusion
Title
IgE-dependent allergy
Description
IgE-dependent allergy will be defined by the appearance of symptoms a few minutes to 2 hours after ingestion of the food, with skin signs (urticaria, angioedema) and/or respiratory symptoms (dyspnea, laryngospasm, cough, bronchospasm ); digestive and neurological signs being potentially common with the diagnosis of FPIES
Time Frame
at 1 year, 2 years, 3 years post inclusion
Title
multiple FPIES
Description
A multiple FPIES will be defined by the presence of clinical symptoms of FPIES for at least two different foods
Time Frame
at 1 year, 2 years, 3 years post inclusion
Title
Atopic comorbidities
Description
Atopic comorbidities will be defined by asthma, allergic rhinitis, atopic dermatitis, and eosinophilic esophagitis
Time Frame
at 1 year, 2 years, 3 years post inclusion

10. Eligibility

Sex
All
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age from 0 to 17 years old, seen in allergologist visit for acute FPIES, due to history of suggestive clinical symptoms, confirmed by the criteria published in 2017 in the JACI (Nowak-Wegrzyn et al, JACI 2017), or by an oral food challenge for diagnosis in the absence of the requested clinical criteria, affiliated to social security (public healthcare system) signed consent of one of the parents or the holder of parental authority Exclusion Criteria: Associated pathology that may contraindicate OFC at the discretion of the investigating physician. In particular justifying permanent treatment with a beta-blocker or an angiotensin-converting enzyme inhibitor.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sibylle BLANC, MD
Phone
0492030841
Email
blanc.si@pediatrie-chulenval-nice.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Dominique Donzeau
Phone
0492034560
Email
donzeau.d@chu-nice.fr
Facility Information:
Facility Name
Chu Angers
City
Angers
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ANNE HOPPE, MD
Facility Name
Chi Robert Ballanger
City
Aulnay-sous-Bois
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ARIANNE NEMNI
Facility Name
Chu Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ELODIE MICHAUD
Facility Name
Hopital Civils de Colmar
City
Colmar
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JESSICA LOGLI
Facility Name
Chu Grenoble
City
Grenoble
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
VIRGINIE JUBIN
Facility Name
Ch Haguenau
City
Haguenau
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
CARINE FAVRE-METZ
Facility Name
Chr Lille Hopital Jeanne de Flandre
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ANTOINE DESCHILDRE
Facility Name
Hopital Saint Vincent de Paul Ghicl
City
Lille
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NICOLAS KALACH
Facility Name
Hopital Civil de Lyon
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PRISCILLE BIERME
Facility Name
Chu Montpellier
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DAVIDE CAIMMI
Facility Name
Chu Nancy
City
Nancy
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
AMANDINE DIVARET-CHAUVEAU
Facility Name
Cabinet Berlioz
City
Nice
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MICHELE BERLIOZ
Facility Name
Hôpitaux Pédiatriques de Nice CHU-Lenval
City
Nice
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sibylle BLANC, MD
Phone
0492030841
Email
blanc.si@pediatrie-chulenval-nice.fr
Facility Name
Aphp Armand Trousseau
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ANAIS LEMOINE
Facility Name
Hopital Ambroise Pare Aphp
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
GREGOIRE BENOIST
Facility Name
Hopital Necker Enfants Malades Aphp
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
GUILLAUME LEZMI
Facility Name
Hopital Robert Debre Aphp
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
FLORE AMAT
Facility Name
Chu Rouen
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
LAURE COUDERC
Facility Name
Cabinet Chabbert
City
Toulouse
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ANNE CHABBERT

12. IPD Sharing Statement

Learn more about this trial

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form

We'll reach out to this number within 24 hrs